Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy

Tumor antigens NY-ESO-1 and p53 both frequently induce spontaneous serum antibody in cancer patients. While NY-ESO-1-specific CD8(+) and CD4(+) circulating T-cells occur mainly in NY-ESO-1-seropositive patients, p53-specific circulating CD8(+) and CD4(+) T-cells are respectively undetectable and com...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuji, Takemasa, Gnjatic, Sacha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382850/
https://www.ncbi.nlm.nih.gov/pubmed/22737632
http://dx.doi.org/10.4161/onci.19310
Descripción
Sumario:Tumor antigens NY-ESO-1 and p53 both frequently induce spontaneous serum antibody in cancer patients. While NY-ESO-1-specific CD8(+) and CD4(+) circulating T-cells occur mainly in NY-ESO-1-seropositive patients, p53-specific circulating CD8(+) and CD4(+) T-cells are respectively undetectable and common in most individuals. Understanding T-cell split tolerance can help define suitable targets for immunotherapy.

Ejemplares similares